Results 11 to 20 of about 278,985 (182)
Neuroprotection by dopamine agonists [PDF]
Journal of neural transmission. Supplementum, 1994 Research on Parkinson's disease has led to new hypotheses concerning the mechanisms of neurodegeneration and to the development of neuroprotective agents. Recent findings of impaired mitochondrial function, altered iron metabolism and increased lipid peroxidation in the substantia nigra of parkinsonian patients emphasize the significance of oxidative ...
Lange, K. W. +5 more
openaire +4 more sources
Dopamine agonists for restless legs syndrome
Advances in Clinical Neuroscience & RehabilitationRestless Legs Syndrome (RLS) is a common neurological disorder characterised by an uncontrollable urge to move the legs. Dopamine agonists are widely used as first or second-line treatments for RLS due to their efficiency in alleviating the symptoms of ...
Pran Phakdeekitcharoen, Michael J Keogh
doaj +2 more sources
Dopamine Agonists and Pathologic Behaviors [PDF]
Parkinson's Disease, 2012 The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as ...
Brendan J. Kelley +2 more
doaj +3 more sources
Cost-effectiveness of dopamine agonists and monoamine oxidase B inhibitors in Parkinson’s disease [PDF]
, 2021 Background: The PD MED study reported small but persistent benefits in patient‐rated mobility scores and quality of life from initiating therapy with levodopa compared with levodopa‐sparing therapies in early Parkinson's disease (PD).
Emma McIntosh +28 more
core +7 more sources
Dopamine genetic risk score predicts impulse control behaviors in Parkinson’s disease
Clinical Parkinsonism & Related Disorders, 2021 Introduction: Up to 40% of Parkinson’s disease patients taking dopamine agonist medication develop impulse control behaviors which can have severe negative consequences.
Alison Hall +5 more
doaj +1 more source
Observations on sleep-disordered breathing in idiopathic Parkinson's disease. [PDF]
PLoS ONE, 2014 BACKGROUND: This study has two main goals: 1.) to determine the potential influence of dopaminergic drugs on sleep-disordered breathing (SDB) in Parkinson's disease (PD) and 2.) to elucidate whether NREM and REM sleep differentially impact SDB severity ...
Philipp O Valko +4 more
doaj +1 more source
Alʹmanah Kliničeskoj Mediciny, 2023 The priority treatment approach for prolactinomas is therapy with dopamine agonists, which allows for elimination of clinical symptoms, normalization of prolactin levels, reduction of the adenoma size and prevention of metabolic abnormalities in the ...
Irena A. Ilovayskaya, Gulnar R. Vagapova
doaj +1 more source
Response of Macroprolactinemia to Dopamine Agonists
Endocrinology Research and Practice, 2008 Macroprolactinemia, defined as hyperprolactinemia with a predominance of the big big prolactin (macroprolactin) isoform, is considered idiopathic and poorly symptomatic. Although macroprolactinemia has been considered to be a cause of apparent resistance
Gonca Tamer +3 more
doaj +3 more sources
Dopamine agonists and antipsychotics [PDF]
European Journal of Endocrinology, 2020 There can potentially be a number of clinical interactions that could adversely affect patient outcomes in a patient with a prolactinoma and psychiatric disease that might require antipsychotic and dopamine agonist treatment. Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size
openaire +2 more sources
Impulsivity in Patients with Parkinson’s Disease [PDF]
Journal of Biomedical & Clinical Research, 2017 In recent years focus has been increasingly placed on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD). ICDs include pathological attraction to gambling, compulsive shopping, compulsive eating and compulsive sexual behaviour and
Rumyana Kuzmanova +2 more
doaj +3 more sources